EN | TR
E-ISSN: 2147-2653
Evalution the Effects of Raloxifene and Risedronate on Serum Biochemical Markers
PDF
Cite
Share
Request
Original Article
VOLUME: 20 ISSUE: 3
P: 110-116
December 2014

Evalution the Effects of Raloxifene and Risedronate on Serum Biochemical Markers

Turk J Osteoporos 2014;20(3):110-116
DOI: 10.4274/tod.78941
Abdurrahman Yeter 1
Vural Kavuncu 2
Fatma Deniz Evcik 3
Ümit Seçil Demirdal 4
Volkan Subaşı 5
Tuncay Çakır 6
1. Özel Fizikomer Fizik Tedavi Ve Rehabilitasyon Merkezi, Gaziantep, Türkiye\R\N
2. Afyon Kocatepe Üniversitesi Tip Fakültesi, Fiziksel Tip Ve Rehabilitasyon Anabilim Dali, Afyonkarahisar, Türkiye
3. Ankara Üniversitesi Haymana Meslek Yüksekokulu, Terapi Ve Rehabilitasyon Anabilim Dali, Ankara, Türkiye
4. Izmir Katip Çelebi Üniversitesi Tip Fakültesi, Fiziksel Tip Ve Rehabilitasyon Anabilim Dali, Izmir, Türkiye
5. Özel Özgür Yasam Fizik Tedavi Ve Rehabilitasyon Merkezi, Mersin, Türkiye
6. Antalya Egitim Ve Arastirma Hastanesi, Fizik Tedavi Ve Rehabilitasyon Klinigi, Antalya, Türkiye
No information available.
No information available
Received Date: 02.07.2014
Accepted Date: 12.08.2014
PDF
Cite
Share
Request

ABSTRACT

Conclusion:

The results of the present study showed us that risedronate and raloxifene were both effective on bone mineral density and the effect of both of them to do not differ not from each other in the treatment of osteoporosis.

Results:

Serum CTX levels were decreased significantly (p<0.001) in all groups from baseline to post therapy of 3 months and this decrease continued to the end of the study. Serum osteocalcin levels were decreased significantly (p<0.001) in treatment groups compared to control group. L1-L4 and femur total BMD was statistically lower in treatment groups compared to control group after 12 months of the therapy (p<0.001 and p<0.05, respectively).

Materials and Methods:

A total of ninety patients with postmenopausal osteoporosis were randomly divided into three groups receiving calcium-vitamin D plus raloxifene, calcium-vitamin D plus risedronate, and only calcium-vitamin D (control group). Serum osteocalcin and collagen type 1 cross-linked C-telopeptide (CTX) were measured before treatment and after 3, 6, 9 and 12 months of treatment. BMD was measured by Dual-Energy X-Ray absorptiometry (DEXA) before treatment and after 12 months of treatment.

Objective:

Osteoporosis a progressive bone disease that is characterized by a decrease in bone mass which can lead to an increased risk of fracture. Osteoporosis is still a global public health problem. In recent years, many new osteoporosis drugs have become available but none of them is totally curative. The aim of the present study was to evaluate and compare the effects of risedronate and raloxifene on bone mineral density (BMD) and bone turnover markers.